NEW YORK, NY / ACCESSWIRE / December 2, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ovid Therapeutics Inc.
("Ovid" or "the Company") (NASDAQ:OVID). Investors who purchased Ovid securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ovid.
The investigation concerns whether Ovid and certain of its officers and/or directors have violated federal securities laws.
On December 1, 2020, Ovid announced results from its Phase 3 NEPTUNE clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome. Dr. Jeremy Levin, Ovid's Chairman, and Chief Executive Officer said, "We are deeply disappointed with the outcome of the NEPTUNE trial which did not achieve its primary endpoint," and continued, "Other than the ongoing ELARA study, we plan to pause our OV101 program in Angelman syndrome pending a full understanding of this outcome and discussions with regulators and investigators." Following this news, Ovid stock dropped to a low of $2.90 per share during intra-day trading on December 2, 2020.
If you are aware of any facts relating to this investigation or purchased Ovid shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/ovid. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: